May 11, 2023 7:00am EDT SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
Apr 13, 2023 8:30am EDT SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
Mar 31, 2023 8:30am EDT SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 30, 2023 7:05am EDT GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Dec 01, 2022 8:00am EST SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
Nov 30, 2022 8:30am EST SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
Nov 17, 2022 8:30am EST SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
Nov 09, 2022 7:00am EST SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 07, 2022 8:30am EST SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi
Nov 03, 2022 8:30am EDT Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection